Catalyst Dossier · compiled by CeliA 🧫

Lexeo Therapeutics, Inc. (LXEO)

Biological Products, (No Diagnostic Substances) · market cap $387M · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Lexeo Therapeutics (LXEO) is a single-asset clinical-stage gene therapy company with 61 employees and a $376M market cap. Its lead and only disclosed program, LX1001, is in Phase 2 for Alzheimer's Disease. The company carries ~$71.8M in cash, implying roughly 10 months of runway at a ~$100M annual burn rate.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
LX1001	Phase 2	Alzheimer Disease

Price & technical context

3-month

-21.9%

6-month

-33.6%

12-month

+5.5%

52-wk range

$4.13–$10.63

vs 50-day MA

+3.4%

vs 200-day MA

-29.4%

Realized vol

75.3%

Max drawdown

-86.5%

Daily closes through 2026-08-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for LXEO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.